ArticleJournal of gastrointestinal oncology2025
Atypical abdominal pain: uncovering malignant peritoneal mesothelioma in suspected Crohn's disease: a case report.
Article in Journal of gastrointestinal oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Malignant peritoneal mesothelioma (MPM) is a rare and aggressive cancer from the serosal membranes of the abdominal cavity. In the United States, MPM accounts for about 10-15% of all mesothelioma cases, and translates into approximately 600 new cases diagnosed annually. It is typically diagnosed in Caucasian individuals, and while asbestos exposure is a well-established risk factor for pleural mesothelioma, its association with peritoneal mesothelioma remains less clear. Clinical symptoms of MPM, such as abdominal pain, bloating, and weight loss, overlap with other gastrointestinal disorders, which often leads to delayed diagnosis. This case report presents a unique instance of MPM initially misdiagnosed as ileal Crohn's disease (CD), highlighting the importance of differential diagnosis in such complex cases. Case Description: A 62-year-old Caucasian male with a history of diverticulitis was referred to an inflammatory bowel disease (IBD) center for reported ileal CD. The patient experienced 3 years of persistent abdominal pain, constipation, fatigue, early satiety, and weight loss. Previous imaging, including computed tomography scans, suggested ileal thickening and inflammatory fat stranding, but no histologic confirmation of CD was obtained. He had been treated with Humira without improvement, and intermittent courses of prednisone provided temporary relief. Despite his diagnosis of CD, his symptoms were unresponsive to standard treatments. Upon further evaluation, Humira levels were undetectable, and magnetic resonance enterography (MRE) yielded no significant findings. A diagnostic laparoscopy was performed, revealing peritoneal mesothelioma, which was confirmed by biopsy as the diffuse, epithelioid type. The diagnosis was supported by positive immunohistochemical staining for calretinin, CK7, and CK5/6. Conclusions: This case underscores the importance of considering a broad differential diagnosis in patients with non-specific abdominal symptoms. Although CD was initially suspected, MPM was ultimately identified through diagnostic laparoscopy and histological analysis. The case highlights the need for comprehensive diagnostic evaluation, including histologic confirmation and objective markers, to accurately differentiate between conditions with similar presentations. Clinicians should maintain a high index of suspicion for rare etiologies, such as peritoneal mesothelioma, particularly in patients with a history of asbestos exposure, to ensure timely and appropriate management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.